STOCK TITAN

Cresco Labs to Report Third Quarter 2023 Financial Results on November 15, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Cresco Labs, the industry leader in branded cannabis products, will report financial results for the third quarter of 2023 on November 15th. The company will host a conference call and webcast to discuss its financial results and provide key business highlights.
Positive
  • None.
Negative
  • None.

CHICAGO--(BUSINESS WIRE)-- Cresco Labs (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) (“Cresco” or “the Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today announced it will report financial results for the third quarter 2023 on Wednesday, November 15th, 2023 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights.

Event: Cresco Labs Third Quarter 2023 Earnings Conference Call

Date: Wednesday, November 15th, 2023

Time: 8:30 am EST

Webcast: LINK

Dial-in: 1-833-470-1428 (US Toll Free), 1-646-904-5544 (US Local)

Access Code: 259018

Archived access to the webcast will be available for one year on the Cresco Labs investor relations website.

About Cresco Labs

Cresco Labs’ mission is to normalize and professionalize the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development and legislative initiatives designed to create the most responsible, respectable and robust cannabis industry possible. Learn more about Cresco Labs’ journey by visiting www.crescolabs.com or following the Company on Facebook, X or LinkedIn.

Media:

Jason Erkes, Cresco Labs

Chief Communications Officer

press@crescolabs.com

Investors:

Megan Kulick, Cresco Labs

Senior Vice President, Investor Relations

investors@crescolabs.com

For general Cresco Labs inquiries:

312-929-0993

info@crescolabs.com

Source: Cresco Labs

FAQ

When will Cresco Labs report its financial results for the third quarter of 2023?

Cresco Labs will report its financial results for the third quarter of 2023 on November 15th.

What is the webcast link for the conference call?

The webcast link for the conference call has not been provided in the press release.

What is the dial-in number for the conference call?

The dial-in number for the conference call is 1-833-470-1428 (US Toll Free) or 1-646-904-5544 (US Local).

Will the webcast be available for replay?

Yes, archived access to the webcast will be available for one year on the Cresco Labs investor relations website.

CRESCO LABS INC

OTC:CRLBF

CRLBF Rankings

CRLBF Latest News

CRLBF Stock Data

675.05M
170.74M
0.6%
7.97%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
Chicago

About CRLBF

cresco labs llc is an illinois medical cannabis company, licensed to develop and operate medical cannabis cultivation centers in police districts 5, 9 and 21, according to illinois’ office of the governor. cresco labs exceeded the state’s rigorous qualifying standards, receiving the highest scores of any cultivation center applicant to obtain three of 18 total awarded cultivation licenses as part of the illinois medical cannabis pilot program.